(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.77%.
Century Therapeutics's earnings in 2026 is -$9,580,000.On average, 7 Wall Street analysts forecast IPSC's earnings for 2026 to be -$105,407,393, with the lowest IPSC earnings forecast at -$144,425,202, and the highest IPSC earnings forecast at -$66,048,111. On average, 5 Wall Street analysts forecast IPSC's earnings for 2027 to be -$99,602,348, with the lowest IPSC earnings forecast at -$137,380,070, and the highest IPSC earnings forecast at -$66,048,111.
In 2029, IPSC is forecast to generate -$91,658,603 in earnings, with the lowest earnings forecast at -$88,064,148 and the highest earnings forecast at -$94,354,444.